Novogene Global Risk Report

🏗️ Operational & Business Continuity

Novogene's recent activities illustrate its strategic expansion and focus on maintaining robust sequencing capabilities. The company has demonstrated foresight in strengthening its operational foundations across key global markets, which is vital for its continued success in the biotechnology research industry. However, these expansions also suggest potential operational risks if the demand does not meet expectations.

• Novogene Europe expanded its sequencing capabilities with the addition of a fifth NovaSeq X Plus system in 🗓 July 3, 2025.
• The establishment of a new subsidiary in Korea was announced to accelerate multi-omics research on 🗓 June 23, 2025.
• Novogene America launched a new single-cell lab in San Jose, CA, based on chromium platform powered by 10x Genomics on 🗓 August 1, 2022.

📜 Innovation & R&D

Innovation remains at the heart of Novogene's strategy. The company continues to push the boundaries of genomic research, reflecting its commitment to staying at the forefront of technological advancements. This commitment to innovation provides significant opportunities but also requires sustained investment in research and expertise.

• On 🗓 June 5, 2025, Novogene expanded its proteomics portfolio by being certified for Olink® services across multiple labs.
• Novogene agreed to buy ten PacBio Sequel Systems for DNA sequencing services on 🗓 January 16, 2017.
• Novogene unveiled an intelligent next generation sequencing delivery platform called Falcon on 🗓 March 24, 2020.

📜 Innovation & R&D

Innovation remains central to Novogene's mission, evidenced by their strategic acquisitions and partnerships. Maintaining a cutting-edge approach in such a competitive field underlines their dedication to advancing genomic research. This continuous investment in R&D showcases the company's pursuit of excellence and leadership in biotechnology.

• On 🗓 June 26, 2024, Novogene conducted a high-resolution 16s rRNA gene next generation sequencing study related to Alzheimer's and Parkinson's disease.
• Comparative transcriptomic immune responses study involving mullet (Mugil cephalus) was published on 🗓 June 26, 2024.
• Novogene America launched the Falcon II, a superpowered robot scientist for autonomously intelligent NGS delivery, on 🗓 September 7, 2022.